Jardiance (empagliflozin)
pCPA File Number:
20956
Negotiation Status:
Concluded with an LOI
Indication(s):
Diabetes Mellitus, Type 2 with high cardiovascular risk
Sponsor/Manufacturer:
Boehringer Ingelheim (Canada) Ltd.
CDA-AMC Project Number:
SR0488-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: